UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
IMMUNEX CORPORATION
------------------------------
(Name of Issuer)
Common Stock, $.01 par value
------------------------------
(Title of Class of Securities)
45252810 2
------------
(CUSIP Number)
Steven M. Odre, Esq. with a copy to:
Senior Vice President, Charles K. Ruck, Esq.
General Counsel and Secretary Latham & Watkins
Amgen Inc. 650 Town Center Drive
One Amgen Center Drive Suite 2000
Thousand Oaks, CA 91320-1799 Costa Mesa, CA 92626
(805) 447-1000 (714) 540-1235
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 16, 2001
-------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
statement because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the
following box [_]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7(b) for other
parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
CUSIP No. 45252810 2
1. NAMES OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Amgen Inc.
I.R.S. Employer Identification No. 95-3540776
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
3. SEC USE ONLY
4. SOURCE OF FUNDS
OO
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e) [_]
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH:
7. SOLE VOTING POWER: 223,378,088 (1)
8. SHARED VOTING POWER: None
9. SOLE DISPOSITIVE POWER: None
10. SHARED DISPOSITIVE POWER: None
11. AGGREGATE AMOUNT BENEFICIALLY
OWNED BY REPORTING PERSON: 223,378,088 (2)
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [_]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 41.0% (3)
14. TYPE OF REPORTING PERSON: CO
2
1. Pursuant to an Agreement and Plan of Merger dated as of December 16, 2001
(the "Merger Agreement"), among Amgen Inc., a Delaware corporation ("Amgen"),
AMS Acquisition Inc., a Washington corporation and wholly-owned subsidiary
of Amgen ("Merger Sub"), and Immunex Corporation, a Washington corporation
("Immunex"), and subject to the conditions set forth therein (including
approval by stockholders of Amgen and shareholders of Immunex and the
expiration or termination of the applicable waiting period under the Hart-
Scott-Rodino Antitrust Improvements Act of 1976), Merger Sub will merge with
and into Immunex and Immunex will become a wholly-owned subsidiary of Amgen
(such events constituting the "Merger"). 223,378,088 shares of Immunex common
stock (the "Shares") are subject to a Shareholder Voting Agreement (the
"Voting Agreement") entered into by Amgen and certain shareholders of Immunex
(See Schedule B attached hereto) (the "Shareholders"). Pursuant to the Voting
Agreement, the Shareholders have agreed to vote (or cause to be voted) their
shares (x) in favor of the approval of the terms of the Merger Agreement, the
Merger and the other transactions contemplated by the Merger Agreement (and
any actions required in furtherance thereof), (y) against any action,
proposal transaction or agreement that would result in a breach in any
respect of any covenant, representation or warranty or any other obligation
or agreement of Immunex contained in the Merger Agreement or of any of the
Shareholders contained in the Voting Agreement, and (z) except with the
written consent of Amgen, against the following actions or proposals (other
than the transactions contemplated by the Merger Agreement): (i) any
Acquisition Proposal (as defined in the Merger Agreement) by a third party;
and (ii) (A) any change in the persons who constitute the board of directors
of Immunex that is not approved in advance by at least a majority of the
persons who were directors of Immunex as of the date of the Voting Agreement
(or their successors who were so approved); (B) any material change in the
present capitalization of Immunex or any amendment of Immunex's articles of
incorporation or bylaws; (C) any other material change in Immunex's corporate
structure or business; or (D) any other action or proposal involving Immunex
or any of its subsidiaries that is intended, or could reasonably be expected,
to prevent, impede, interfere with, delay, postpone or adversely affect the
transactions contemplated by the Merger Agreement. The Shareholders may vote
the Shares on all other matters. As part of the Voting Agreement, the
Shareholders granted an irrevocable proxy to Amgen with respect to the
voting of the Shares for the matters covered by the Voting Agreement.
2. Amgen expressly disclaims beneficial ownership of any of the shares of
Immunex common stock covered by the Voting Agreement.
3. Based on the number of shares of Immunex common stock outstanding as of
December 1, 2001 (as represented by Immunex in the Merger Agreement
discussed in Item 4 below), the number of shares of Immunex common stock
indicated represents approximately 41.0% of the outstanding shares of
Immunex common stock.
3
Item 1. Security and Issuer.
This statement on Schedule 13D (this "Statement") relates to the
common stock of Immunex Corporation, a Washington corporation (sometimes
referred to herein as "Issuer" or "Immunex"). The principal executive
offices of Immunex are located at 51 University Street, Seattle, WA 98101.
Item 2. Identity and Background.
(a)-(c), (f) The name of the corporation filing this Statement is
Amgen Inc., a Delaware corporation ("Amgen"). The address of Amgen's
principal business is One Amgen Center Drive, Thousand Oaks, CA 91320.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets human therapeutics based on advances in cellular
and molecular biology. The name, citizenship, business address and present
principal occupation of each executive officer and director of Amgen is
listed on Schedule A attached hereto.
(d) Neither Amgen nor, to Amgen's knowledge, any person named on
Schedule A attached hereto is required to disclose legal proceedings
pursuant to Item 2(d).
(e) Neither Amgen nor, to Amgen's knowledge, any person named on
Schedule A attached hereto is required to disclose legal proceedings
pursuant to Item 2(e).
Item 3. Source and Amount of Funds or Other Consideration.
As an inducement for Amgen to enter into the Merger Agreement
described in Item 4 and in consideration thereof, certain shareholders of
Immunex listed on Schedule B attached hereto (the "Shareholders") entered
into a Shareholder Voting Agreement dated as of December 16, 2001, a copy
of which is attached as Exhibit 2 (the "Voting Agreement"). Amgen did not
pay additional consideration to the Shareholders in connection with the
execution and delivery of the Voting Agreement.
Item 4. Purpose of Transaction.
(a)-(b) Pursuant to an Agreement and Plan of Merger dated as of
December 16, 2001 (the "Merger Agreement"), among Amgen, AMS Acquisition
Inc., a Washington corporation and wholly-owned subsidiary of Amgen
("Merger Sub"), and Immunex, and subject to the conditions set forth
therein (including approval by stockholders of Amgen and shareholders of
Immunex and the expiration or termination of the applicable waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976), Merger Sub
will merge with and into Immunex and Immunex will become a wholly-owned
subsidiary of Amgen (such events constituting the "Merger"). Once the
Merger is consummated, Merger Sub will cease to exist as a corporation and
all of the business, assets, liabilities and obligations of Merger Sub will
be merged into Immunex with Immunex remaining as the surviving corporation
(the "Surviving Corporation").
As a result of the Merger, each outstanding share of Immunex common
stock, other than (i) shares owned by Merger Sub, Amgen or any wholly-owned
subsidiary of Amgen, and (ii) dissenting shares, will be converted into the
right to receive (a) .440 (the "Exchange Ratio") of a share of Amgen common
stock (the "Common Stock Consideration") and (b) $4.50 in cash (the "Cash
Consideration," and together with the Common Stock Consideration, the
"Merger Consideration"). All such shares of Immunex common stock will no
longer be outstanding and will automatically be canceled and retired and
cease to exist, and each certificate previously
4
representing any such shares shall thereafter represent the right to
receive the Merger Consideration payable in respect of such shares of
Immunex common stock.
The Shareholders have, by executing the Voting Agreement, agreed to
vote the 223,378,088 shares of Immunex common stock (the "Shares")
beneficially owned by them as described below. Pursuant to the Voting
Agreement, the Shareholders have agreed, at every Immunex shareholders
meeting and on every action or approval by written consent in lieu of such
a meeting, to vote (or cause to be voted) their shares (x) in favor of the
approval of the terms of the Merger Agreement, the Merger and the other
transactions contemplated by the Merger Agreement (and any actions required
in furtherance thereof), (y) against any action, proposal, transaction or
agreement that would result in a breach in any respect of any covenant,
representation or warranty or any other obligation or agreement of Immunex
contained in the Merger Agreement or of any Shareholder contained in the
Voting Agreement, and (z) except with the written consent of Amgen, against
the following actions or proposals (other than the transactions
contemplated by the Merger Agreement): (i) any Acquisition Proposal (as
defined in the Merger Agreement) by a third party; and (ii) (A) any change
in the persons who constitute the board of directors of Immunex that is not
approved in advance by at least a majority of the persons who were
directors of Immunex as of the date of the Voting Agreement (or their
successors who were so approved); (B) any material change in the present
capitalization of Immunex or any amendment of Immunex's articles of
incorporation or bylaws; (C) any other material change in Immunex's
corporate structure or business; or (D) any other action or proposal
involving Immunex or any of its subsidiaries that is intended, or could
reasonably be expected, to prevent, impede, interfere with, delay, postpone
or adversely affect the transactions contemplated by the Merger Agreement.
The Shareholders may vote the Shares on all other matters. The Voting
Agreement terminates upon the earliest to occur of (i) the mutual consent
of Amgen and American Home Products Corporation, (ii) the effective time of
the Merger and (iii) the date of termination of the Merger Agreement. See
Section 6.1 of the Voting Agreement, items (iv) and (v), for additional
termination events. As part of the Voting Agreement, the Shareholders
granted an irrevocable proxy to Amgen with respect to the voting of the
Shares for the matters covered by the Voting Agreement.
The purpose of the transactions under the Voting Agreement is to
enable Amgen and Immunex to consummate the transactions contemplated under
the Merger Agreement.
(c) Not applicable.
(d) Upon the consummation of the Merger, the directors of Merger Sub
immediately prior to the effective time of the Merger will be the directors
of the Surviving Corporation , until their respective successors are
duly elected or appointed and qualified. Upon consummation of the Merger,
the officers of Merger Sub immediately prior to the effective time of the
Merger will be the initial officers of the Surviving Corporation, until
their respective successors are duly appointed.
(e) Other than as a result of the Merger described in Item 4(a) above,
not applicable.
(f) Not applicable.
(g) At the effective time of the Merger, the articles of incorporation
of Immunex shall be amended in their entirety to read as the articles of
incorporation of Merger Sub (except that the name of Immunex will remain
Immunex Corporation), and such articles of incorporation will be the
articles of incorporation of the Surviving Corporation until thereafter
changed or amended in accordance with applicable law. At the effective time
of the Merger, the Bylaws of Merger Sub,
5
as in effect immediately prior to the effective time of the Merger, shall
be the Bylaws of the Surviving Corporation, until thereafter changed or
amended as provided therein or by applicable law.
(h)-(i) If the Merger is consummated as planned, the Immunex common
stock will be deregistered under the Securities Act of 1933, as amended,
and delisted from the Nasdaq National Market.
(j) Other than described above, Amgen currently has no plan or
proposals which relate to, or may result in, any of the matters listed in
Items 4(a)-(j) of Schedule 13D (although Amgen reserves the right to
develop such plans).
References to, and descriptions of, the Merger, the Merger Agreement
and the Voting Agreement as set forth herein are qualified in their
entirety by reference to the copies of the Merger Agreement and the Voting
Agreement, respectively, included as Exhibits 1 and 2, respectively, to
this Statement, and such agreements are incorporated herein in their
entirety where such references and descriptions appear.
Item 5. Interest in Securities of the Issuer.
(a)-(b) As a result of the Voting Agreement, Amgen may be deemed to
be the beneficial owner of 223,378,088 shares of Immunex common stock. Such
Immunex common stock constitutes approximately 41.0% of the issued and
outstanding shares of Immunex common stock based on the number of shares of
Immunex common stock outstanding as of December 1, 2001 (as represented by
Immunex in the Merger Agreement discussed in Item 4 above). Amgen may be
deemed to have the sole power to vote the Shares with respect to those
matters described above. However, Amgen (i) is not entitled to any other
rights as a shareholder of Immunex as to the Shares and (ii) disclaims any
beneficial ownership of the shares of Immunex common stock which are
covered by the Voting Agreement.
To the knowledge of Amgen, no person listed on Schedule A hereto has
an equity or other ownership interest in Immunex.
(c) As described in Items 3 and 4 of this Statement, Amgen entered
into the Voting Agreement and the Merger Agreement within the last 60 days.
(d) To the knowledge of Amgen, no person, other than the Shareholders
as set forth on Schedule B, has the right to receive or the power to direct
the receipt of dividends from, or the proceeds from the sale of, the
securities of Immunex deemed to be beneficially owned by Amgen.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understanding or Relationships With Respect to
Securities of the Issuer.
Other than the Merger Agreement and the Voting Agreement, to the
knowledge of Amgen, there are no contracts, arrangements, understandings or
relationships among the persons named in Item 2 and Schedule A and between
such persons and any other person with respect to any securities of
Immunex, including, but not limited to, transfer or voting of any of the
securities, finder's fees, joint ventures, loan or option arrangement, puts
or calls, guarantees of profits, division of profits or loss, or the giving
or withholding of proxies.
6
Item 7. Material to be Filed as Exhibits.
The following documents are filed as exhibits:
1. Agreement and Plan of Merger, dated December 16, 2001, by and among
Amgen, Merger Sub and Immunex (filed as an exhibit to the Form 8-K Current
Report dated December 16, 2001 on December 17, 2001 and incorporated herein
by reference).
2. Shareholder Voting Agreement, dated December 16, 2001, by and among
Amgen and certain shareholders of Immunex as listed on Schedule B hereto
(filed as an exhibit to the Form 8-K Current Report dated December 16, 2001
on December 17, 2001 and incorporated herein by reference).
7
SIGNATURES
After reasonable inquiry and to the best knowledge and belief of the
undersigned, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: December 21, 2001
AMGEN INC.
By: /s/ Kevin W. Sharer
--------------------------------------
Name: Kevin W. Sharer
Title: Chairman of the Board,
Chief Executive Officer and
President
8
SCHEDULE A
DIRECTORS AND EXECUTIVE OFFICERS OF AMGEN INC.
The name, citizenship, business address, and present principal occupation
or employment of each of the directors and executive officers of Amgen Inc. are
set forth below.
---------------------------------------------------------------------------------------------------
Name* Principal Occupation Business Address
---------------------------------------------------------------------------------------------------
Executive Officers
------------------
---------------------------------------------------------------------------------------------------
Kevin W. Sharer Chairman of the Board, Chief Amgen Inc.
Executive Officer and President of One Amgen Center Drive
Amgen Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
Richard D. Nanula Executive Vice President, Amgen Inc.
Finance, Strategy and Communications, One Amgen Center Drive
and Chief Financial Thousand Oaks, CA 91320-1799
Officer of Amgen
---------------------------------------------------------------------------------------------------
Brian M. McNamee Senior Vice President, Human Amgen Inc.
Resources of Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
Dennis M. Fenton Executive Vice President of Amgen Inc.
Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
Steven M. Odre Senior Vice President, General Amgen Inc.
Counsel and Secretary of Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
George J. Morrow Executive Vice President, Worldwide Amgen Inc.
Sales and Marketing of Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
George Morstyn Senior Vice President, Development, Amgen Inc.
and Chief Medical Officer of Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
Roger M. Perlmutter Executive Vice President, Research Amgen Inc.
and Development of Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
Fabrizio Bonanni Senior Vice President, Quality and Amgen Inc.
Compliance of Amgen One Amgen Center Drive
Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
Directors
---------
---------------------------------------------------------------------------------------------------
David Baltimore President, California Institute of Technology
California Institute of Technology Office of the President, 204-31
1200 E. California Blvd.
Pasadena, California 91125
---------------------------------------------------------------------------------------------------
William K. Bowes, Jr. General Partner, U.S. Venture
U.S. Venture Partners
Partners 2180 Sand Hill Road, Suite 300
Menlo Park, California 94025
---------------------------------------------------------------------------------------------------
Jerry D. Choate (Retired) Chairman of the Board and 33971 Selva Road
Chief Executive Officer Allstate Suite 130
Insurance Company Dana Point, California 92629
---------------------------------------------------------------------------------------------------
9
---------------------------------------------------------------------------------------------------
Name* Principal Occupation Business Address
---------------------------------------------------------------------------------------------------
Frederick W. Gluck Consultant McKinsey & Company, Inc.
McKinsey & Company, 400 South Hope Street, Suite 700
Inc. Los Angeles, California 90071
---------------------------------------------------------------------------------------------------
Franklin P. Johnson, Jr. General Partner Asset Management Partners
Asset Management Partners 2275 East Bayshore Road
Suite 150
Palo Alto, California 94303
---------------------------------------------------------------------------------------------------
Steven Lazarus Managing General Partner ARCH Venture Partners, L.P.
ARCH Venture Partners, L.P. 8725 W. Higgins Road Suite 290
Chicago, Illinois 60631
---------------------------------------------------------------------------------------------------
Gilbert S. Omenn Executive Vice President for Medical University of Michigan
Affairs at the University of 1301 Catherine Drive
Michigan, Chief Executive Officer of Room M7324
the University of Ann Arbor, Michigan 48109-0626
Michigan Health System and Professor
of Internal Medicine, Human Genetics
and Public Health
---------------------------------------------------------------------------------------------------
Judith C. Pelham President and Chief Executive Officer Trinity Health
Trinity Health 27870 Cabnot Drive
Novi, Michigan 48377-2920
---------------------------------------------------------------------------------------------------
J. Paul Reason President and Chief Operating Officer Metro Machine Corporation
Metro Machine Corporation 200 Ligon Street
Norfolk, Virginia 23523
---------------------------------------------------------------------------------------------------
Donald B. Rice President and Chief Executive Officer Agensys, Inc.
Agensys, Inc. 1545 17th Street
Santa Monica, California 90404
---------------------------------------------------------------------------------------------------
Kevin W. Sharer Chairman of the Board, President and Amgen Inc.
Chief Executive Officer One Amgen Center Drive
Amgen Inc. Thousand Oaks, CA 91320-1799
---------------------------------------------------------------------------------------------------
--------------
*Each person listed is a citizen of the United States.
10
SCHEDULE B
Shareholders Party to a Voting Agreement with Amgen Inc.
Shareholder Party to Voting Agreement Shares Beneficially Owned
------------------------------------- -------------------------
American Home Products Corporation 223,378,088
MDP Holdings, Inc. 180,153,032
Lederle Parenterals, Inc. 43,225,056
11
INDEX OF EXHIBITS
1. Agreement and Plan of Merger, dated December 16, 2001, by and among Amgen,
Merger Sub and Immunex (filed as an exhibit to the Form 8-K Current Report dated
December 16, 2001 on December 17, 2001 and incorporated herein by reference).
2. Shareholder Voting Agreement, dated December 16, 2001, by and among Amgen
and certain shareholders of Immunex as listed on Schedule B hereto (filed as an
exhibit to the Form 8-K Current Report dated December 16, 2001 on December 17,
2001 and incorporated herein by reference).
12